Nifedipine
Based on 31 publication(s) in Google Scholar
Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.91%
- CAS No.: 21829-25-4
- Formule: C17H18N2O6
- Masse moléculaire:346.33
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nifedipine
More- Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. [Abstract]
- Nat Commun. 2026 Jan 8;17(1):1253. [Abstract]
- Sci Adv. 2026 Mar 6;12(10):eadw0891. [Abstract]
- Cell Commun Signal. 2022 Aug 26;20(1):130. [Abstract]
- Phytomedicine. 2021 Nov:92:153687. [Abstract]
- Cell Death Discov. 2026 Jun 19. [Abstract]
- Biol Psychiatry. 2021 Jun 1;89(11):1084-1095. [Abstract]
- Alzheimers Res Ther. 2025 Dec 1;17(1):253. [Abstract]
- Phytother Res. 2024 Jan;38(1):384-399. [Abstract]
- Cell Prolif. 2026 Jan 26:e70177. [Abstract]
- J Med Chem. 2019 Sep 12;62(17):7961-7975. [Abstract]
- Small Sci. 2025 Jul 14;5(10):2500095. [Abstract]
- Sci Signal. 2020 Nov 24;13(659):eaax0273. [Abstract]
- Pharmaceuticals (Basel). 2025 Sep 21;18(9):1420. [Abstract]
- Eur J Pharmacol. 2022 Dec 5:936:175343. [Abstract]
- Front Endocrinol. 2018 Nov 30:9:721. [Abstract]
- Microchem J. 2025 Nov 24;220:116331.
- ACS Omega. 2020 Oct 12;5(41):26551-26561. [Abstract]
- World J Stem Cells. 2026 May 26;18(5).
- Cell Calcium. 2026 Mar:134:103122. [Abstract]
- FASEB J. 2024 Aug 15;38(15):e23878. [Abstract]
- J Endocrinol Invest. 2025 Feb;48(2):317-332. [Abstract]
- J Cell Commun Signal. 2023 Dec;17(4):1309-1321. [Abstract]
- Drug Metab Dispos. 2025 Aug;53(8):100116. [Abstract]
- Exp Cell Res. 2025 Apr 1;447(1):114515. [Abstract]
- Neuroscience. 2021 Nov 1:475:220-228. [Abstract]
- J Neurophysiol. 2020 Jan 1;123(1):277-288. [Abstract]
- Biocell. 2026 Jan 23.
- Biol Pharm Bull. 2024;47(12):2119-2126. [Abstract]
- bioRxiv. 2026 Jul 10:2026.07.06.736331.
- medRxiv. 2025 May 21.
Customer Validation & Images
-
Cell Imaging/Staining
-
Others
-
Others
-
Others
-
Bio/Physico-chemical Assay
Voir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: NIF
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 31673316] |
| C6-BU-1 | IC50 |
1000 nM
Compound: 1
|
IKCa channel inhibition was determined measuring ionomycin-induced Rb+ efflux of pre loaded rat C6BU1 glioma cell in comparison with Nifedipine
IKCa channel inhibition was determined measuring ionomycin-induced Rb+ efflux of pre loaded rat C6BU1 glioma cell in comparison with Nifedipine
|
[PMID: 12873483] |
| Calvarial osteoblast | EC50 |
1.54 μM
Compound: nifedipine
|
Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation after 21 days by alizarin red-S staining based spectrophotometric analysis
Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation after 21 days by alizarin red-S staining based spectrophotometric analysis
|
[PMID: 23214410] |
| CHO | EC50 |
0.4 μM
Compound: 53
|
Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx
Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx
|
[PMID: 20356305] |
| CHO | IC50 |
0.05 μM
Compound: Nifedipine
|
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit
|
[PMID: 22761000] |
| CHO | IC50 |
0.01 μM
Compound: nifedipine
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| HCT-116 | IC50 |
>100 μM
Compound: NIF
|
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 31673316] |
| HEK293 | IC50 |
3.6 nM
Compound: nifedipine
|
Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2b in rabbit expressed in HEK293 cells
Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2b in rabbit expressed in HEK293 cells
|
[PMID: 18303827] |
| HEK293 | IC50 |
45 nM
Compound: nifedipine
|
Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2a in rabbit expressed in HEK293 cells
Displacement of (+)-[5-methyl-3H]PN200-100 from L type calcium channel Cav1.2a in rabbit expressed in HEK293 cells
|
[PMID: 18303827] |
| HEK293 | IC50 |
0.06 μM
Compound: 1
|
Inhibition of L-type calcium channel expressed in HEK293 cells
Inhibition of L-type calcium channel expressed in HEK293 cells
|
[PMID: 19004630] |
| HEK293 | IC50 |
0.086 μM
Compound: Nif
|
Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis
Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis
|
[PMID: 23586669] |
| HEK-293T | IC50 |
1.5 μM
Compound: Nifedipine
|
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
|
[PMID: 23122865] |
| HEK-293T | IC50 |
46 μM
Compound: Nifedipine
|
Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
|
[PMID: 23122865] |
| HepG2 | IC50 |
9.4 μM
Compound: Nifedipine
|
Cytotoxicity against human HepG2 cells after 24 hrs by LDH release assay
Cytotoxicity against human HepG2 cells after 24 hrs by LDH release assay
|
[PMID: 30554954] |
| L929 | IC50 |
6.1 μM
Compound: 1
|
Inhibition of human Kv1.5 channel expressed in mouse L929 cells by EP voltage clamp technique
Inhibition of human Kv1.5 channel expressed in mouse L929 cells by EP voltage clamp technique
|
[PMID: 19004630] |
| LLC-MK2 | IC50 |
101.75 μM
Compound: Nifedipine
|
Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay
Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay
|
[PMID: 20934347] |
| LLC-MK2 | IC50 |
588.73 μM
Compound: Nifedipine
|
Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay
Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay
|
[PMID: 20934347] |
| LLC-PK1 | IC50 |
472 μM
Compound: Nifedipine
|
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM) in MDR1-expressing LLC-PK1 cells
|
[PMID: 12128170] |
| MCF7 | IC50 |
>100 μM
Compound: NIF
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 31673316] |
| MM1.S | IC50 |
57.9 μM
Compound: NIF
|
Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay
|
[PMID: 31673316] |
| NIH-3T3-G185 | IC50 |
113 μM
Compound: Nifedipine
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11743742] |
| Sf21 | IC50 |
30.7 μM
Compound: Nifedipine
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
45.4 μM
Compound: Nifedipine
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| SH-SY5Y | IC50 |
1.35 μM
Compound: nifedipine
|
Inhibition of human Cav1.3 channel in human SH-SY5Y cells assessed as 70 mM K+ induced calcium elevation compound treated 15 mins before stimulus by Fluo-4/AM assay
Inhibition of human Cav1.3 channel in human SH-SY5Y cells assessed as 70 mM K+ induced calcium elevation compound treated 15 mins before stimulus by Fluo-4/AM assay
|
[PMID: 24754640] |
| SH-SY5Y | IC50 |
22 μM
Compound: Nifedipine
|
Inhibition of voltage-dependent L-type calcium channel in 70 mM K+-induced human SH-SY5Y cells assessed as blocking of depolarization-induced Ca2+ uptake by Fluo-4/AM dye based fluorescence microplate reader assay
Inhibition of voltage-dependent L-type calcium channel in 70 mM K+-induced human SH-SY5Y cells assessed as blocking of depolarization-induced Ca2+ uptake by Fluo-4/AM dye based fluorescence microplate reader assay
|
[PMID: 31724859] |
Nifedipine (BAY-a-1040) (100 μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells, and treatment of nifedipine (10 or 100 μM) plus FAC induces a significant reduction in cell viability, but there are no significant differences in viability between the control cells and the cells treated with 100 μM of FAC or 1 and 10 μM of nifedipine.Nifedipine (BAY-a-1040) (1, 10, or 100 μM) significantly increases iron level in WKPT-0293 Cl.2 cells. Nifedipine treatment also increases expression of TfR1, DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells. In addition, co-treatment with nifedipine (100 μM) and FAC (100 μM) increases TfR1, DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells[2]. Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations. The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine. The combination of nifedipine plus NS-1619 (Ca2+-activated K+ [BKCa] channel opener) reduces the inhibitory effect of each drug[3]. Nifedipine (BAY-a-1040) (2 μM) significantly inhibits P. capsici mycelial growth and sporulation. Nifedipine (BAY-a-1040)-induced inhibition of mycelial growth is calcium-dependent. Nifedipine (0.5 μM) increases P. capsici sensitivity to H2O2 in a calcium-dependent manner[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 21829-25-4
-
Appearance Solid
-
Masse moléculaire 346.33
-
Formule C17H18N2O6
-
Color Off-white to gray
-
SMILES
O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2[N+]([O-])=O)OC
-
Synonyms
BAY-a-1040
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications (31)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. [Abstract]2024 Jan 4;31(1):52-70.e8. PMID: 38181751 -
Nat Commun
2026 Jan 8;17(1):1253. PMID: 41507162 -
Sci Adv
A worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger. [Abstract]2026 Mar 6;12(10):eadw0891. PMID: 41790895 -
Cell Commun Signal
How filopodia respond to calcium in the absence of a calcium-binding structural protein: non-channel functions of TRP. [Abstract]2022 Aug 26;20(1):130. PMID: 36028898 -
Phytomedicine
Aesculin suppresses the NLRP3 inflammasome-mediated pyroptosis via the Akt/GSK3β/NF-κB pathway to mitigate myocardial ischemia/reperfusion injury. [Abstract]2021 Nov:92:153687. PMID: 34482222 -
Cell Death Discov
Thioredoxin system dysregulation and calpain activation drive myocardial disulfidptosis via pathological disulfide bonds remodeling. [Abstract]2026 Jun 19. PMID: 42321161 -
Biol Psychiatry
Takeda G Protein-Coupled Receptor 5 Modulates Depression-like Behaviors via Hippocampal CA3 Pyramidal Neurons Afferent to Dorsolateral Septum. [Abstract]2021 Jun 1;89(11):1084-1095. PMID: 33536132 -
Alzheimers Res Ther
Ceftriaxone alleviates mitochondrial damage through the inhibition of extrasynaptic NMDA receptor-mediated changes in intracellular calcium levels to improve cognitive deficits in APP/PS1 mice. [Abstract]2025 Dec 1;17(1):253. PMID: 41327376
Nifedipine purchased from MedChemExpress. Usage Cited in: Alzheimers Res Ther. 2025 Dec 1;17(1):253. [Abstract]
Nifedipine (5 µM, 1 min) decreased the neuronal cytoplasmic Ca2+ levels induced by 20 µM glutamate.
-
Phytother Res
Phenolic acids from Prunella vulgaris alleviate cardiac remodeling following myocardial infarction partially by suppressing NLRP3 activation. [Abstract]2024 Jan;38(1):384-399. PMID: 37992723 -
Cell Prolif
Lactate Accelerates Early Angiogenesis and Bone Regeneration Through Macrophage M1 Polarisation. [Abstract]2026 Jan 26:e70177. PMID: 41587535 -
J Med Chem
Germacrane Sesquiterpenoids as a New Type of Anticardiac Fibrosis Agent Targeting Transforming Growth Factor β Type I Receptor. [Abstract]2019 Sep 12;62(17):7961-7975. PMID: 31408333 -
Small Sci
Built-In Electric Field Accelerates Nanotopography-Mediated Enhancement of Vascularized Osseointegration via Cav1.2/Piezo/Ca2+/PI3K Signaling. [Abstract]2025 Jul 14;5(10):2500095. PMID: 41058722 -
Sci Signal
Airway relaxation mechanisms and structural basis of osthole for improving lung function in asthma. [Abstract]2020 Nov 24;13(659):eaax0273. PMID: 33234690
Nifedipine purchased from MedChemExpress. Usage Cited in: Sci Signal. 2020 Nov 24;13(659):eaax0273. [Abstract]
Nifedipine (10 µM, 30 min) relaxed 0.3 μM ACh-constricted mouse airways.
Nifedipine purchased from MedChemExpress. Usage Cited in: Sci Signal. 2020 Nov 24;13(659):eaax0273. [Abstract]
Pretreatment with nifedipine (10 µM, 30 min) reduced ACh-induced airway constriction by about 25% but did not affect osthole-induced relaxation in mouse airways.
-
Pharmaceuticals (Basel)
2025 Sep 21;18(9):1420. PMID: 41011287
Nifedipine purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Sep 21;18(9):1420. [Abstract]
Nifedipine (0.01 µM, 30 min) inhibited contractions induced by Ca2+ influx, keeping the contraction force below 0.1 g even at the highest calcium concentration of 10 mM.
-
Eur J Pharmacol
Chemerin-9 in paraventricular nucleus increases sympathetic outflow and blood pressure via glutamate receptor-mediated ROS generation. [Abstract]2022 Dec 5:936:175343. PMID: 36306926 -
Front Endocrinol
A Type IIb, but Not Type IIa, GnRH Receptor Mediates GnRH-Induced Release of Growth Hormone in the Ricefield Eel. [Abstract]2018 Nov 30:9:721. PMID: 30555419
Nifedipine purchased from MedChemExpress. Usage Cited in: Front Endocrinol. 2018 Nov 30:9:721. [Abstract]
Nifedipine (4 µM, 4 h) abolished the stimulation of Gh release by GnRH1 or GnRH3 in primary cultured pituitary cells from mixed-sex rice field eels.
-
-
ACS Omega
2020 Oct 12;5(41):26551-26561. PMID: 33110983 -
-
Cell Calcium
A NOX2-independent mechanism of Hv1 channel activation promotes inflammatory cytokine release from BV-2 microglia via intracellular Ca2+ mobilisation. [Abstract]2026 Mar:134:103122. PMID: 41581267 -
FASEB J
Pilocarpine mediated excessive calcium accumulation leads to ciliary muscle cell senescence and apoptosis. [Abstract]2024 Aug 15;38(15):e23878. PMID: 39120551 -
J Endocrinol Invest
2025 Feb;48(2):317-332. PMID: 39527372 -
J Cell Commun Signal
Insights into the mediation of Ca2+ signaling in the promoting effects of LETX-VI on the synthesis and release of dopamine. [Abstract]2023 Dec;17(4):1309-1321. PMID: 37702818 -
Drug Metab Dispos
Age-dependent pharmacokinetics of nifedipine in spontaneous hypertensive rats are associated with changes in gut microbiota and hepatic CYP3A1 expression. [Abstract]2025 Aug;53(8):100116. PMID: 40716236 -
Exp Cell Res
Investigating the effects of TRPV4 and Cav1.2 channels in 3D culture for promoting the differentiation of BMSCs at various stages. [Abstract]2025 Apr 1;447(1):114515. PMID: 40073957 -
Neuroscience
2021 Nov 1:475:220-228. PMID: 34509547 -
J Neurophysiol
Sequential activation of multiple persistent inward currents induces staircase currents in serotonergic neurons of medulla in ePet-EYFP mice. [Abstract]2020 Jan 1;123(1):277-288. PMID: 31721638 -
-
Biol Pharm Bull
Cynaropicrin Increases [Ca2+]i and Ciliary Beat Frequency in Human Airway Epithelial Cells by Inhibiting SERCA. [Abstract]2024;47(12):2119-2126. PMID: 39710380 -
-
Solvant et solubilité
DMSO : 100 mg/mL (288.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Cell viability is assessed using an MTT assay. Briefly, a total of 25 μL MTT (1 g/L in PBS) is added to each well before incubation is conducted at 37°C for 4 h. The assay is stopped by the addition of a 100 μL lysis buffer (20% SDS in 50% N’Ndimethylformamide, pH 4.7). Optical density (OD) is measured at the 570 nm wavelength by the use of an ELX-800 microplate assay reader and the results are expressed as a percentage of the absorbance measured in the control cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
All the 30 rats are randomLy distributed into three equal groups of ten animals each. Group 1 (control) receive olive oil for the 8 weeks. Group 2 and Group 3 receive a combination of CsA (30 mg/kg body weight) and Nf (50 mg/kg body weight) in olive oil for 8 weeks. In Group 3 rats, Azi (10 mg/kg body weight) is added to this regimen, in the 5th week. The total study period is 8 weeks.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ratre MS, et al. Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats. J Indian Soc Periodontol. 2016 Jul-Aug;20(4):396-401. [Content Brief]
[2]. Carvajal JA, et al. The Synergic In Vitro Tocolytic Effect of Nifedipine Plus Ritodrine on Human Myometrial Contractility. Reprod Sci. 2017 Apr;24(4):635-640. [Content Brief]
[3]. Yu SS, et al. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60 [Content Brief]
[4]. Liu P, et al. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8874 mL | 14.4371 mL | 28.8742 mL | 72.1855 mL |
| 5 mM | 0.5775 mL | 2.8874 mL | 5.7748 mL | 14.4371 mL | |
| 10 mM | 0.2887 mL | 1.4437 mL | 2.8874 mL | 7.2185 mL | |
| 15 mM | 0.1925 mL | 0.9625 mL | 1.9249 mL | 4.8124 mL | |
| 20 mM | 0.1444 mL | 0.7219 mL | 1.4437 mL | 3.6093 mL | |
| 25 mM | 0.1155 mL | 0.5775 mL | 1.1550 mL | 2.8874 mL | |
| 30 mM | 0.0962 mL | 0.4812 mL | 0.9625 mL | 2.4062 mL | |
| 40 mM | 0.0722 mL | 0.3609 mL | 0.7219 mL | 1.8046 mL | |
| 50 mM | 0.0577 mL | 0.2887 mL | 0.5775 mL | 1.4437 mL | |
| 60 mM | 0.0481 mL | 0.2406 mL | 0.4812 mL | 1.2031 mL | |
| 80 mM | 0.0361 mL | 0.1805 mL | 0.3609 mL | 0.9023 mL | |
| 100 mM | 0.0289 mL | 0.1444 mL | 0.2887 mL | 0.7219 mL |
Nifedipine Related Classifications
HY-B0284 Related Classifications
Powered by Bioz